echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > DS-8201 is not the endpoint: the development of camptothecin and its derivative ADC and strategies to enhance therapeutic efficacy

    DS-8201 is not the endpoint: the development of camptothecin and its derivative ADC and strategies to enhance therapeutic efficacy

    • Last Update: 2022-09-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Over the past 20 years, topoisomerase inhibitors have been widely used as anti-cancer drugs


    DNA topoisomerases are key enzymes for stabilizing DNA hyperpixes and resolving tangles, and are essential



    TOP1 inhibitors have been studied extensively, several of which have been approved by




    Although the efficacy of TOP1-ADC's TOP1 inhibitors in the treatment of cancer has been greatly improved, there is still a lot of room for improvement in the therapeutic effect of TOP1-ADC (Table 3


    • DNA damage regulator
    PARP can promote DNA stabilization and repair


    Top1 inhibitors have shown considerable potential as anti-tumor therapeutics; However, their poor pharmacokinetics and extra-target toxicity hinder their clinical application


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.